Domainex and its new Cambridge facility fit for a King
A winner in last September’s Business Weekly Awards, Domainex intends to facilitate further collaborations with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions from the new building at Howard Group’s Unity Campus at Pampisford.
The opening was officiated by Julie Spence, HM Lord-Lieutenant of Cambridgeshire, who also presented the King’s Award for Enterprise: International Trade 2023 to Domainex CEO, Dr Tom Mander.
The three-storey, state-of-the-art facility provides over 24,000 sq ft for Domainex’s expanding biology/bioanalytical departments. It provides a more than three-fold increase on the previous footprint to allow continued, rapid expansion of people and equipment to support Domainex’s ambition to provide innovative and customised drug discovery services to a growing client-base globally.
The facility will be able to house more than 100 scientists including biochemists, biophysicists, cell biologists, protein scientists, bioanalysts and structural biologists.
With the existing Chemistry Centre of Excellence at Chesterford Research Park, the combined footprint of Domainex’s research facilities in the Cambridge life science hub now exceeds 44,000 sq ft.
The King’s Award for Enterprise: International Trade 2023, recognises the company’s outstanding growth in international trade over three years, which amounted to a more than one hundred per cent increase in international revenues during the period.
This growth was achieved entirely organically and is a testament to the company’s excellent reputation and commitment to delivering high-quality drug discovery services for its life science clients.
CEO Dr Tom Mander, commented: “We are deeply honoured to receive the prestigious King’s Award from HM Lord-Lieutenant of Cambridgeshire and are privileged that the Lord-Lieutenant has also opened our new building.
“Our exciting new facility will enable us to continue to expand the range of our services and will help bring much needed treatments to patients faster and more effectively.”
Dr Trevor Askwith, Head of Biology, added that Domainex was continually investing in cutting-edge technologies and developing new services. He said: “We launched a new cryo-EM service last year and recently expanded our suite of biophysical instrumentation by adding spectral shift technology, a third, multi-channel Grating Coupled Interferometry WAVEdelta system and a PEAQ-ITC instrument. The additional space will allow for further expansion and innovation.”
Employing over 100 scientists, 95 per cent of whom are educated to at least Master’s degree level, Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. Domainex is named on more than 60 patent applications of numerous candidate drugs.
The Lord Lieutenant commented: “It was my pleasure to open Domainex's new Biology Centre of Excellence and to present the King's Award for Enterprise to CEO Tom Mander.
“The King's Awards are the most prestigious awards available to UK businesses, are highly competitive and only awarded to the best. I would like to congratulate Domainex on this fantastic achievement and on the opening of the new facility which will allow the company to expand the high-quality, innovative drug discovery services for which it is globally renowned.”
